Trials / Unknown
UnknownNCT03422029
Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients
Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Dotatate in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of GEP-NEN
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 177Lu-Dotatate PRRT | PRRT using 177Lu-Dotatate 100-150mCi will be performed 8-weekly. A maximum of 8 cycles will be administered. Other: Amino-Acid Solution The Amino-Acid Solution (AAS) to be used in this study, infused over 4-6 h, starting 30 min before PRRT |
Timeline
- Start date
- 2018-01-31
- Primary completion
- 2020-12-30
- Completion
- 2021-12-30
- First posted
- 2018-02-05
- Last updated
- 2020-02-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03422029. Inclusion in this directory is not an endorsement.